# PROFOUND (Weihe multi-omic multi-cancer case-control study)

Source: https://onco.cc/trials/profound-mced/  
OnCo record `profound-mced` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese case-control study of about 16,700 people building a multi-omic blood test for several cancers.

## Summary

PROFOUND (NCT06217900) is an observational study sponsored by Shanghai Weihe Medical Laboratory Co., Ltd with Peking University People's Hospital. It develops and validates in a blinded set a machine-learning multi-cancer early detection model from blood multi-omic analysis.

The registry record, read on 29 October 2026, gives its status as active, not recruiting, with an estimated 16,666 participants, a start on 28 December 2023 and primary completion expected on 31 October 2026.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-29
- Also known as: PROFOUND
- Registry id: NCT06217900
- Phase: observational
- Setting: People newly diagnosed with cancer and people without cancer at Chinese hospitals, developing and blind-testing a multi-omic machine-learning model
- Sponsor: Shanghai Weihe Medical Laboratory Co., Ltd. with Peking University People's Hospital
- Enrolled: 16666

## Sources

- ClinicalTrials.gov NCT06217900: https://clinicaltrials.gov/study/NCT06217900

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/profound-mced.json